Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry drives low uptake for EU-US parallel advice

This article was originally published in SRA

Executive Summary

The future of the parallel scientific advice pilot launched between the US and the European Union several years ago is “a never ending debate”, according to the European Medicines Agency’s senior medical officer. Inevitably, the status of the ailing programme was brought up during a Q&A session at the Drug Information Association’s 45th annual meeting held in San Diego, US, on 21-25 June.

You may also be interested in...



Global medtech alliance approves six new member associations

An emerging alliance of medical technology industry associations representing innovative companies that currently develop and manufacture 85% of the world's medical devices, diagnostics and equipment has approved the membership applications of six more associations, bringing the total number of members to 19.

Global medtech alliance approves six new member associations

An emerging alliance of medical technology industry associations representing innovative companies that currently develop and manufacture 85% of the world's medical devices, diagnostics and equipment has approved the membership applications of six more associations, bringing the total number of members to 19.

US FDA scrutiny of DTC genetic tests continues

The US FDA's devices unit has written to three genetic testing companies warning them that they may be marketing their products and services without clearance by the agency.

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel